No abstract available.
Bone Marrow Transplantation* ; Bone Marrow*

No abstract available.
Bone Marrow Transplantation* ; Bone Marrow*

No abstract available.
Bone Marrow Transplantation* ; Bone Marrow*

No abstract available.
Bone Marrow Transplantation* ; Bone Marrow*

The bone marrow transplantation is a most modern technique and applied in Vietnam to treat the malignant hematological diseases. This paper introduced the bone marrow heterotransplantation and the autologous peripheral blood stem cell transplantation. 3 patients (1 male; 2 female) received transplantation (bone marrow fluid was extracted from patient’s brothers) for the treatment of the chronic myeloid leukemia and severe thalassemia and 17 patients received the autologous peripheral blood stem cell transplantation for treatment of acute myeloid leukemia, chronic myeloid leukemia, acute lyphoid leukemia and lymphoma. The results have shown that the longest survival duration was 42 months after the autologous peripheral blood stem cell transplantation. The patients had a normal life such as learning, working and social activities. After 2 months of transplantation, the average disease free duration of 10 patients with AML and 6 patients with ALL were 27 months, and 30-40 months, respectively. This was an great encouragement.
Bone Marrow Transplantation ; Bone marrow ; Bone and bones

BACKGROUND: We performed this study to compare response rate and survival according to treatment modalities, such as allogeneic bone marrow transplantation (BMT), immunosuppressive therapy (IS) and androgen therapy in patients with aplastic anemia (AA). METHODS: Medical records of one hundred and thirty-seven patients who diagnosed with aplastic anemia at the Asan Medical Center from September 1989 to December 2000 were retrospectively analyzed. RESULTS: Forty-one patients received supportive care only. Ninety-five out of 96 treated patients were evaluable for response. In severe AA group (N=79), the response rate according to treatment modalities was 25.0% in the androgen group (N=4), 30.3% in the ALG or ATG group (N=33), 25.0% in the cyclosporine (CSA) group (N=8), 44.4% in the ATG plus CSA group (N=9), and 73.8% in the BMT group (N=23) (P<0.001). Five- and 10-year survival of overall patients was 67.5% and 50.9%, respectively. Ten-year survival according to disease severity was 42.3% in severe AA group and 75.8% in non-severe AA group (P=0.0043). Five- year survival according to treatment modalities in patients with severe AA was 75.0% in the androgen group, 49.0% in the ALG or ATG group, 75.0% in the CSA group, and 88.9% in the ATG plus CSA group. Five-year survival was 82.6% in the BMT group and 57.7% in the IS group (P=0.0259). CONCLUSION: This study showes that BMT resulted in significantly better response rate and overall survival compared to IS in patients with severe AA.
Bone Marrow Transplantation

No abstract available.
Bone Marrow Transplantation* ; Bone Marrow* ; Child* ; Humans

No abstract available.
Anemia* ; Bone Marrow Transplantation* ; Bone Marrow*

Graft-versus-host disease (GVHD) is the major cause of morbidity or mortality after marrow transplantation. The intestinal involvement of GVHD is associated with high graft failure. It is usually difficult to diagnose gastrointestinal (GI) GVHD because symptom is nonspecific, and diagnostic criteria in endoscopic and histologic findings lack the gold standard. We reviewed 7 patients with GI GVHD proven by endoscopic biopsy from September 1999 to June 2003. The common GI symptoms at the time of endoscopy were diarrhea and abdominal pain. Four patients were acute GVHD, two acute and chronic GVHD, and one chronic GVHD. The interval from bone marrow transplantation to GVHD diagnosis by histological examination varied from 18 days to 259 days. The skin was involved in 5 patients. Two cases showed normal endoscopic finding. From these results, endoscopic biopsy is a essential tool in evaluating patients with GI complaints after bone marrow transplantation.
Mortality ; Biopsy ; Bone Marrow Transplantation

The blood transfusion is necessary while the donor’s marrow has not been growed yet. The transfused blood products must assure completely the safety principles for disease transmission, the blood products is not infected the MCV and removed the leucocyte usually transfused after 4- 12 weeks of transplantation with the suitable dosage for individuals. Condensed platalet is transfused after 6-12 weeks of transplantation. It should maintain the amount of thrombocyte in the peripheral blood within 50-100x109/lit, the dose is different from one patient to another.
Blood transfusion ; Bone marrow ; Transplantation